Phosphatidylserine
Brain-cell phospholipid with modest, FDA-qualified support for age-related memory.
Moderate evidence
🧠Nootropic
Evidence tier
Moderate
Research weight
Citations
12 verified / 12
Classification
Nootropic
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Phosphatidylserine?
Phosphatidylserine is a nootropic used for may produce small improvements in memory and learning in older adults with age-associated memory complaints or mild cognitive impairment.. NutriDex grades the human evidence as Moderate. Phosphatidylserine is a phospholipid concentrated in neuronal cell membranes and marketed as a memory-support nootropic. A 2022 systematic review and meta-analysis (9 studies, 961 participants, 100–300 mg/day for 6 weeks to 6 months) concluded it has a positive effect on memory in older adults with cognitive decline, and a 2024 RCT in older adults with mild cognitive impairment found small improvements in short-term memory, reasoning, and arithmetic over placebo. However, effect sizes are generally small and independent reviewers (e.g., the Alzheimer's Drug Discovery Foundation) note the changes are often not large enough to be clearly clinically relevant, with most trials being short and using differing PS sources that complicate comparison. The U.S. FDA granted only a 'qualified' health claim, explicitly stating that the supporting evidence is very limited and preliminary and that there is little scientific agreement that PS reduces dementia risk. Modern products are derived from soy or sunflower rather than the bovine-brain PS used in early studies. Overall the evidence is best characterized as moderate but modest: a plausible, well-tolerated option for age-related memory, not a proven treatment for dementia.
Purported Benefits
✓May produce small improvements in memory and learning in older adults with age-associated memory complaints or mild cognitive impairment.
✓Pooled trial data suggest a positive effect on memory in elderly with cognitive decline, though effect sizes are small and not clearly clinically meaningful.
✓Generally well tolerated, making it a low-risk option to trial for subjective age-related memory concerns.
✓Holds a U.S. FDA 'qualified' (heavily caveated) health claim relating it to reduced risk of dementia/cognitive dysfunction in the elderly.
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Memory in older adults with cognitive decline/MCIMeta-analysis and several RCTs show positive memory effects, but effect sizes small and not clearly clinically meaningful. | Moderate | ↑ benefit · small | 4 |
| Dementia risk reductionFDA granted only a qualified claim, stating evidence is very limited/preliminary with little scientific agreement. | Preliminary | ↔ mixed | 1 |
| Working memory in healthy/middle-aged adultsTwo RCTs (often combination formulas) show small working-memory gains; confounded by co-ingredients (DHA, coffee cherry). | Preliminary | ↑ benefit · small | 2 |
| Exercise/stress cortisol bluntingSmall RCTs (n=10-75) show blunted exercise/stress cortisol at high doses; very small samples, mostly surrogate endpoints. | Preliminary | ↑ benefit · moderate | 3 |
Dosing & Compounds
Typical Dose
100–300 mg/day, typically split into 2–3 doses with food; most cognitive trials used 100 mg three times daily.
Active Compounds
Safety & Cautions
Generally well tolerated; most reported side effects are mild and transient, mainly gastrointestinal upset and headache, with insomnia possible at higher doses (above ~300 mg/day) or when taken late in the day. Soy-derived products are unsuitable for people with soy allergy—sunflower-derived PS is an alternative. PS may theoretically enhance the effect of anticoagulant/antiplatelet drugs (e.g., warfarin, heparin); people on blood thinners should consult a clinician first, though clinical trials have not reported increased bleeding or clotting events. Data in pregnancy and breastfeeding are lacking, so it should be avoided in these groups; safety in children is not established. Older bovine-brain–derived PS carried theoretical prion (BSE) risk and has been discontinued—choose plant-derived (soy/sunflower) products. It is a supplement, not a treatment for diagnosed dementia or Alzheimer's disease; anyone with significant cognitive decline should seek medical evaluation rather than self-treating. Educational only — always check with your doctor or pharmacist before combining Phosphatidylserine with any medicine.
Key Studies ★ 12 studies
Systematic review / meta-analysis
9 studies / 961 participants
✓ Full text
Systematic review and meta-analysis found phosphatidylserine (100–300 mg/day, 6 weeks–6 months) had a positive effect on memory in older adults with cognitive decline, with no adverse effects reported.
RCT
Neurology and Therapy 2023
✓ Source
Double-blind RCT in 138 healthy adults aged 40-65 with self-reported memory problems: 42 days of a whole coffee cherry extract plus phosphatidylserine formulation improved numeric working-memory COMPASS task accuracy vs placebo.
Regulatory statement
regulatory decision
✓ Source
FDA permitted only a qualified health claim, stating that very limited and preliminary research suggests PS may reduce dementia/cognitive-dysfunction risk in the elderly and that there is little scientific evidence supporting the claim.
RCT
Vakhapova et al. 2010 (PS-DHA memory RCT)
✓ PubMed
15-week double-blind, placebo-controlled RCT in 157 non-demented elderly with memory complaints; PS containing omega-3 (PS-DHA) significantly improved verbal immediate recall vs placebo, with larger gains in immediate/delayed recall and learning in the subgroup with better baseline cognition.
RCT
Kato-Kataoka et al. 2010 (Soy-PS memory RCT)
✓ PubMed
6-month double-blind RCT in 78 elderly Japanese (50-69 y) with memory complaints; soybean PS (100 or 300 mg/day) significantly increased memory scores from baseline in those with relatively low baseline scores (mainly delayed verbal recall), whereas placebo did not change; no safety signals.
RCT
Hellhammer et al. 2014 (PAS stress RCT)
✓ PubMed
Double-blind, placebo-controlled RCT in 75 healthy men; 42 days of soy PS/phosphatidic acid complex at 400 mg PS + 400 mg PA/day normalized the hyper-responsive ACTH (p=0.010), salivary cortisol (p=0.043) and serum cortisol (p=0.035) responses to an acute social stress test in chronically high-stressed subjects; the 200 mg dose had no effect.
Randomized double-blind placebo-controlled trial
190 (95 PS, 95 placebo)
✓ PubMed
In Chinese older adults with mild cognitive impairment, a 12-month phosphatidylserine-containing supplement significantly improved short-term memory (β=0.60), reasoning and arithmetic versus placebo, with effects partly mediated by raised serum n-3 fatty acids.
Randomized controlled trial
149
✓ PubMed
Landmark RCT in age-associated memory impairment found 100 mg bovine-cortex phosphatidylserine three times daily for 12 weeks improved learning and everyday memory tasks versus placebo, most notably in lower-performing subjects.
RCT
Starks et al. 2008 (exercise endocrine RCT)
✓ PubMed
Double-blind, placebo-controlled crossover RCT in 10 healthy men; 10 days of 600 mg/day PS blunted exercise-induced cortisol (peak ~39% lower, AUC ~35% lower vs placebo, p<0.05) and raised the testosterone-to-cortisol ratio AUC (~184%); no effect on growth hormone or lactate.
Review
Farhan 2026
✓ PubMed
Beyond apoptosis: Annexin A5 as a multifunctional regulator in the pathophysiology of diabetes and its complications
Expert evidence review
narrative review
✓ Source
Independent expert assessment concluded phosphatidylserine may offer some memory benefit but that cognitive improvements in trials are typically slight, short-term, and not clearly clinically meaningful, limited by differing PS sources.
Review
Kingsley 2006 (Sports Medicine review)
✓ PubMed
Authoritative narrative review of PS supplementation in exercising humans: bovine-cortex PS 800 mg/day moderated exercise-induced HPA-axis (cortisol) changes, soy PS 800 mg/day reduced overtraining cortisol and improved well-being/soreness, and short-term soy PS 750 mg/day improved high-intensity cycling capacity; soy PS preferred over bovine due to prion risk; effective oral dose may vary between individuals.